ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

2-Year Results on Renal Function and Safety for Everolimus plus Reduced-Exposure Calcineurin Inhibitor in Living Donor Kidney Transplant Recipients

T. Yagisawa,1 N. Ishikawa,1 N. Goto,2 I. Nakajima,3 O. Kamisawa,4 S. Fuchinoue.3

1Division of Renal and Transplantation, Jichi Medical University, Shimotsuke, Japan
2Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan
3Surgery, Kidney Center, Tokyo Women's University, Tokyo, Japan
4Medical Division, Novartis Pharma K.K., Tokyo, Japan.

Meeting: 2015 American Transplant Congress

Abstract number: D134

Keywords: Immunosuppression, Kidney transplantation

Session Information

Date: Tuesday, May 5, 2015

Session Name: Poster Session D: Kidney Immunosuppression: Drug Minimization

Session Time: 5:30pm-6:30pm

 Presentation Time: 5:30pm-6:30pm

Location: Exhibit Hall E

Related Abstracts
  • Everolimus Plus Reduced-Exposure Calcineurin Inhibitor Versus Mycophenolate Mofetil Plus Standard-Exposure Calcineurin Inhibitor: 2-Year Results in Living Donor Kidney Transplant Recipients
  • Post Hoc Subgroup Analysis of ZEUS: Outcome on Renal Function, Efficacy and Safety in Living-Donor Kidney Transplant Recipients After Conversion from a Calcineurin Inhibitor to an Everolimus Based Regimen: 5 Year Follow-Up Data

Purpose: The long-term effects of everolimus (EVR) with reduced cyclosporine (rCsA) exposure over 24 months on renal function and safety (viral infection) were assessed in kidney transplant recipients (KTxR) receiving allografts from living donors.

Methods: A1202 core study was a 12-month, multicenter, randomized, open-label, non-inferiority study designed to investigate the efficacy and safety of concentration-controlled EVR (1.5 mg/day starting dose, target trough level 3-8 ng/mL) with rCsA exposure versus mycophenolate mofetil (MMF; 2g) with standard CsA exposure in de novo KTxR in Japan. The 24-month study was an extension to the 12-month core study. Here, a retrospective analysis on living donor population from the A1202 study (including 12 months core and extension study results until 24 months) was done and included a further sub-analysis based on the donor age (<50 vs. ≥50 years) to describe the renal function parameter.

Results: At Month 24, the EVR group showed a numerically higher calculated GFR (cGFR, mL/min/1.73 m2) than MMF group (median values, EVR: 58.40 vs. MMF: 54.50; p=0.149). Further, better renal function was observed in EVR group for donor age <50 years (median cGFR: EVR: 78.6 vs. MMF: 53.5) while the MMF group showed a marginal improvement in the median cGFR than EVR group (EVR: 51.8 vs. MMF: 54.5) for donor age ≥50 years. No deaths were reported during the study. Similar incidence of SAEs (60%) were reported for each treatment group and the adverse events (>85%) were mild to moderate in severity in either group. A higher proportion of recipients in MMF group had serious infections (36% EVR vs. 46% MMF) including serious viral infections (14% EVR vs. 32% MMF) with more MMF recipients being CMV test positive (4% EVR vs. 16% MMF). Further, increased blood creatinine was reported for MMF recipients (4% EVR vs. 12% MMF) although slightly higher incidences of proteinuria (10% EVR vs. 4% MMF) were observed in EVR recipients.

Conclusion: The long-term results over 24 months in living donor KTxR demonstrated a numerically higher renal function (cGFR) and less serious infections in EVR group compared to MMF group.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Yagisawa T, Ishikawa N, Goto N, Nakajima I, Kamisawa O, Fuchinoue S. 2-Year Results on Renal Function and Safety for Everolimus plus Reduced-Exposure Calcineurin Inhibitor in Living Donor Kidney Transplant Recipients [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/2-year-results-on-renal-function-and-safety-for-everolimus-plus-reduced-exposure-calcineurin-inhibitor-in-living-donor-kidney-transplant-recipients/. Accessed April 20, 2021.

« Back to 2015 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
    • Assessment of Anti-A and Anti-B Antibody Titers in Different IVIG Preparations: Correlation with Risk for Hemolysis

    Visit Our Partner Sites

    American Transplant Congress (ATC)

    Visit the official site for the American Transplant Congress »

    American Journal of Transplantation

    The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

    American Society of Transplantation (AST)

    An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

    American Society of Transplant Surgeons (ASTS)

    The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

    Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

    Privacy Policy | Terms of Use

    loading Cancel
    Post was not sent - check your email addresses!
    Email check failed, please try again
    Sorry, your blog cannot share posts by email.
    This site uses cookies: Find out more.